Adamis Pharmaceuticals Co. (NASDAQ:ADMP) Short Interest Down 67.7% in August

Posted by Defense World Staff on Aug 26th, 2023

Adamis Pharmaceuticals Co. (NASDAQ:ADMP – Get Free Report) was the target of a large drop in short interest in the month of August. As of August 15th, there was short interest totalling 98,900 shares, a drop of 67.7% from the July 31st total of 305,900 shares. Based on an average trading volume of 2,080,000 shares, the days-to-cover ratio is presently 0.0 days. Currently, 1.1% of the company’s stock are sold short.

Institutional Investors Weigh In On Adamis Pharmaceuticals

An institutional investor recently bought a new position in Adamis Pharmaceuticals stock. Armistice Capital LLC purchased a new position in shares of Adamis Pharmaceuticals Co. (NASDAQ:ADMP – Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 14,500,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,681,000. Armistice Capital LLC owned about 8.71% of Adamis Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

Adamis Pharmaceuticals Price Performance

NASDAQ:ADMP opened at $0.83 on Friday. Adamis Pharmaceuticals has a 52 week low of $0.77 and a 52 week high of $26.18. The firm has a 50 day moving average of $1.75 and a 200 day moving average of $5.97.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on Adamis Pharmaceuticals in a report on Thursday, August 17th. They issued a “sell” rating on the stock.

View Our Latest Research Report on Adamis Pharmaceuticals

About Adamis Pharmaceuticals

(Get Free Report)

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose.